- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 10-K Annual report
- 10.21 Offer Letter Agreement, Between Exelixis, Inc. and J. Scott Garland
- 10.26 Compensation Information for Non-employee Directors
- 10.83 Termination Agreement Between Exelixis, Inc. and Sanofi
- 10.91 Exclusive License Agreement Between Exelixis, Inc. and Merck
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification Required by Rule 13A-14(A) or Rule 15D-14(A)
- 31.2 Certification Required by Rule 13A-14(A) or Rule 15D-14(A)
- 32.1 Certification by the CEO and CFO As Required by Rule 13A-14(B) or 15D-14(B)
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-176674, 333-157825, 333-159280, 333-124536, 333-113472, 333-102770, 333-82724, 333-82722, 333-57026, 333-54868, 333-52434, 333-35862, 333-133237, 333-147063 and 333-149834, 333-165389), and the Registration Statement on Form S-3 and related Prospectus of Exelixis, Inc. (No. 333-152166) of our reports dated February 22, 2012 with respect to the consolidated financial statements of Exelixis, Inc. and the effectiveness of internal control over financial reporting of Exelixis, Inc., included in this Annual Report (Form 10-K) for the year ended December 30, 2011.
/s/ Ernst & Young LLP
Redwood City, California
February 22, 2012